UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators

JNCI : Journal of the National Cancer Institute, 2000-03, Vol.92 (5), p.376-387

2000

Volltextzugriff (PDF)

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

Annals of oncology, 2017-11, Vol.28 (11), p.2754-2760

2017

Volltextzugriff (PDF)

Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial

Annals of oncology, 2016-08, Vol.27 (8), p.1579-1585

2016

Volltextzugriff (PDF)

Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies

Leukemia, 2001, Vol.15 (1), p.1-9

SENDEROWICZ, A. M

2001

Volltextzugriff (PDF)

Small molecule modulators of cyclin-dependent kinases for cancer therapy

Oncogene, 2000-12, Vol.19 (56), p.6600-6606

Senderowicz, A M

2000

Volltextzugriff (PDF)

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Journal of clinical oncology, 2001-04, Vol.19 (8), p.2319-2333

2001

Volltextzugriff (PDF)

Targeting cell cycle and apoptosis for the treatment of human malignancies

Current opinion in cell biology, 2004-12, Vol.16 (6), p.670-678

Senderowicz, Adrian M

2004

Volltextzugriff (PDF)

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms

Journal of clinical oncology, 1998-09, Vol.16 (9), p.2986-2999

1998

Volltextzugriff (PDF)

Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol

Cancer research (Chicago, Ill.), 1999-09, Vol.59 (18), p.4634-4641

1999

Volltextzugriff (PDF)

Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases

Cancer research (Chicago, Ill.), 1999-06, Vol.59 (11), p.2566-2569

1999

Volltextzugriff (PDF)

Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials

Investigational new drugs, 1999-08, Vol.17 (3), p.313-320

Senderowicz, A M

1999

Volltextzugriff (PDF)

P21-dependent G1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

British journal of cancer, 2000, Vol.83 (6), p.817-825

2000

Volltextzugriff (PDF)

Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes

Cancer research (Chicago, Ill.), 1999-11, Vol.59 (21), p.5433-5437

1999

Volltextzugriff (PDF)

Overexpression of the ATP-binding Cassette Half-Transporter, ABCG2 (MXR/BCRP/ABCP1), in Flavopiridol-resistant Human Breast Cancer Cells

Clinical cancer research, 2001-01, Vol.7 (1), p.145-152

2001

Volltextzugriff (PDF)

Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation

The Journal of biological chemistry, 2003-08, Vol.278 (32), p.30339-30347

2003

Volltextzugriff (PDF)

Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication

The Journal of biological chemistry, 2000-09, Vol.275 (37), p.28345-28348

2000

Volltextzugriff (PDF)

Galeterone: A Triple Action Drug for the Treatment of Castration-Resistant Prostate Cancer: ARMOR1 Results

Annals of oncology, 2013-03, Vol.24, p.i7-i7

Senderowicz, A.

2013

Volltextzugriff (PDF)

Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol

Blood, 1998-01, Vol.91 (2), p.458-465

1998

Volltextzugriff (PDF)

A Phase I Study of Combination Therapy with Immunotoxins IgG-HD37-Deglycosylated Ricin A Chain (dgA) and IgG-RFB4-dgA (Combotox) in Patients with Refractory CD19(+), CD22(+) B Cell Lymphoma

Clinical cancer research, 2000-04, Vol.6 (4), p.1302-1313

2000

Volltextzugriff (PDF)

Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin

The Journal of biological chemistry, 1994-05, Vol.269 (21), p.14869-14871

1994

Volltextzugriff (PDF)

Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2)

Life sciences (1973), 2003-10, Vol.73 (22), p.2841-2854

2003

Volltextzugriff (PDF)

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

The Journal of clinical investigation, 1998-11, Vol.102 (9), p.1674-1681

1998

Volltextzugriff (PDF)

Societal challenges of precision medicine: Bringing order to chaos

European journal of cancer (1990), 2017-10, Vol.84, p.325-334

2017

Volltextzugriff (PDF)

Induction of Apoptosis and Inhibition of c-erbB-2 in Breast Cancer Cells by Flavopiridol

Clinical cancer research, 2000-01, Vol.6 (1), p.223-229

2000

Volltextzugriff (PDF)

Jasplakinolide's Inhibition of the Growth of Prostate Carcinoma Cells In Vitro With Disruption of the Actin Cytoskeleton

JNCI : Journal of the National Cancer Institute, 1995-01, Vol.87 (1), p.46-51

1995

Volltextzugriff (PDF)

1 – 25 von 293

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(239)
Mit Volltextzugriff
(253)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(133)
Life Sciences & Biomedicine
(115)
Humans
(106)
Biological And Medical Sciences
(57)
Oncology
(55)
Medical Sciences
(52)
Pharmacology. Drug Treatments
(43)
Female
(42)
Antineoplastic Agents
(41)
Animals
(38)
Cyclin-Dependent Kinases - Antagonists & Inhibitors
(33)
Male
(32)
Neoplasms - Drug Therapy
(28)
Adult
(25)
Chemotherapy
(24)
Family Planning
(24)
Antineoplastic Agents - Pharmacology
(20)
Antineoplastic Agents - Therapeutic Use
(20)
Arts & Humanities
(20)
Flavopiridol
(20)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial

Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies

Small molecule modulators of cyclin-dependent kinases for cancer therapy

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Targeting cell cycle and apoptosis for the treatment of human malignancies

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms

Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol

Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases

Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials

P21-dependent G1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes

Overexpression of the ATP-binding Cassette Half-Transporter, ABCG2 (MXR/BCRP/ABCP1), in Flavopiridol-resistant Human Breast Cancer Cells

Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation

Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication

Galeterone: A Triple Action Drug for the Treatment of Castration-Resistant Prostate Cancer: ARMOR1 Results

Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol

A Phase I Study of Combination Therapy with Immunotoxins IgG-HD37-Deglycosylated Ricin A Chain (dgA) and IgG-RFB4-dgA (Combotox) in Patients with Refractory CD19(+), CD22(+) B Cell Lymphoma

Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin

Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2)

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

Societal challenges of precision medicine: Bringing order to chaos

Induction of Apoptosis and Inhibition of c-erbB-2 in Breast Cancer Cells by Flavopiridol

Jasplakinolide's Inhibition of the Growth of Prostate Carcinoma Cells In Vitro With Disruption of the Actin Cytoskeleton

Suchergebnisse filtern